Gene-edited CAR T cells: going the distance in B-ALL

Affiliations

¹ Division of Pediatric Hematology Oncology, Department of Pediatrics, University of Florida, Gainesville, FL.
² Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.

Editorial

John A Ligon et al. Blood Adv. 2025.

. 2025 Sep 23;9(18):4755-4756.

doi: 10.1182/bloodadvances.2025017508.

¹ Division of Pediatric Hematology Oncology, Department of Pediatrics, University of Florida, Gainesville, FL.
² Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.

No abstract available

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Long-term outcomes of genome-edited "universal" CAR19 T cells for relapsed/refractory B-ALL at a single pediatric center.
Guardo D, Mishra AK, Rashed H, Gilmour K, Adams S, Pinner D, Sauer M, Vora A, Veys P, Pavasovic V, Rao K, Qasim W. Guardo D, et al. Blood Adv. 2025 Sep 23;9(18):4750-4754. doi: 10.1182/bloodadvances.2025016366. Blood Adv. 2025. PMID: 40601899 Free PMC article.

1. Guardo D, Mishra AK, Rashed H, et al. Long term outcomes of genome edited 'universal' CAR19 T-cells for relapsed/refractory B-ALL at a single pediatric centre. Blood Adv. 2025;9(18):4750–4754. - PubMed
1. Qasim W, Zhan H, Samarasinghe S, et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med. 2017;9(374) - PubMed
1. Benjamin R, Graham C, Yallop D, et al. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet. 2020;396(10266):1885–1894. - PMC - PubMed
1. Ottaviano G, Georgiadis C, Gkazi SA, et al. Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia. Sci Transl Med. 2022;14(668) - PubMed
1. Pulsipher MA, Han X, Maude SL, et al. Next-generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia. Blood Cancer Discov. 2022;3(1):66–81. - PMC - PubMed